Exelixis Earlier Announced Cabozantinib Compared With Placebo Reduced Risk Of Disease Progression Or Death In Patients With Pancreatic NET And In Patients With Extra-Pancreatic NET
Portfolio Pulse from Charles Gross
Exelixis, Inc. (NASDAQ:EXEL) announced results from a phase 3 trial of cabozantinib, which showed significant improvements in progression-free survival for patients with advanced pancreatic and extra-pancreatic neuroendocrine tumors. The company plans to discuss these results with the U.S. Food and Drug Administration.
October 22, 2023 | 2:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exelixis' phase 3 trial results for cabozantinib showed significant improvements for patients with neuroendocrine tumors, which could potentially lead to FDA approval and increased sales.
The positive results from the phase 3 trial of cabozantinib indicate that the drug is effective in treating neuroendocrine tumors. This could lead to FDA approval, which would allow Exelixis to market and sell the drug, potentially increasing the company's revenues and positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100